Can we mitigate the psychological impacts of social isolation using behavioural activation? Long-term results of the UK BASIL urgent public health COVID-19 pilot randomised controlled trial and living systematic review.
Adult psychiatry
Depression & mood disorders
Journal
Evidence-based mental health
ISSN: 1468-960X
Titre abrégé: Evid Based Ment Health
Pays: England
ID NLM: 100883413
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
23
06
2022
accepted:
20
09
2022
pubmed:
13
10
2022
medline:
22
12
2022
entrez:
12
10
2022
Statut:
ppublish
Résumé
Behavioural and cognitive interventions remain credible approaches in addressing loneliness and depression. There was a need to rapidly generate and assimilate trial-based data during COVID-19. We undertook a parallel pilot RCT of behavioural activation (a brief behavioural intervention) for depression and loneliness (Behavioural Activation in Social Isolation, the BASIL-C19 trial ISRCTN94091479). We also assimilate these data in a living systematic review (PROSPERO CRD42021298788) of cognitive and/or behavioural interventions. Participants (≥65 years) with long-term conditions were computer randomised to behavioural activation (n=47) versus care as usual (n=49). Primary outcome was PHQ-9. Secondary outcomes included loneliness (De Jong Scale). Data from the BASIL-C19 trial were included in a metanalysis of depression and loneliness. The 12 months adjusted mean difference for PHQ-9 was -0.70 (95% CI -2.61 to 1.20) and for loneliness was -0.39 (95% CI -1.43 to 0.65).The BASIL-C19 living systematic review (12 trials) found short-term reductions in depression (standardised mean difference (SMD)=-0.31, 95% CI -0.51 to -0.11) and loneliness (SMD=-0.48, 95% CI -0.70 to -0.27). There were few long-term trials, but there was evidence of some benefit (loneliness SMD=-0.20, 95% CI -0.40 to -0.01; depression SMD=-0.20, 95% CI -0.47 to 0.07). We delivered a pilot trial of a behavioural intervention targeting loneliness and depression; achieving long-term follow-up. Living meta-analysis provides strong evidence of short-term benefit for loneliness and depression for cognitive and/or behavioural approaches. A fully powered BASIL trial is underway. Scalable behavioural and cognitive approaches should be considered as population-level strategies for depression and loneliness on the basis of a living systematic review.
Sections du résumé
BACKGROUND
Behavioural and cognitive interventions remain credible approaches in addressing loneliness and depression. There was a need to rapidly generate and assimilate trial-based data during COVID-19.
OBJECTIVES
We undertook a parallel pilot RCT of behavioural activation (a brief behavioural intervention) for depression and loneliness (Behavioural Activation in Social Isolation, the BASIL-C19 trial ISRCTN94091479). We also assimilate these data in a living systematic review (PROSPERO CRD42021298788) of cognitive and/or behavioural interventions.
METHODS
Participants (≥65 years) with long-term conditions were computer randomised to behavioural activation (n=47) versus care as usual (n=49). Primary outcome was PHQ-9. Secondary outcomes included loneliness (De Jong Scale). Data from the BASIL-C19 trial were included in a metanalysis of depression and loneliness.
FINDINGS
The 12 months adjusted mean difference for PHQ-9 was -0.70 (95% CI -2.61 to 1.20) and for loneliness was -0.39 (95% CI -1.43 to 0.65).The BASIL-C19 living systematic review (12 trials) found short-term reductions in depression (standardised mean difference (SMD)=-0.31, 95% CI -0.51 to -0.11) and loneliness (SMD=-0.48, 95% CI -0.70 to -0.27). There were few long-term trials, but there was evidence of some benefit (loneliness SMD=-0.20, 95% CI -0.40 to -0.01; depression SMD=-0.20, 95% CI -0.47 to 0.07).
DISCUSSION
We delivered a pilot trial of a behavioural intervention targeting loneliness and depression; achieving long-term follow-up. Living meta-analysis provides strong evidence of short-term benefit for loneliness and depression for cognitive and/or behavioural approaches. A fully powered BASIL trial is underway.
CLINICAL IMPLICATIONS
Scalable behavioural and cognitive approaches should be considered as population-level strategies for depression and loneliness on the basis of a living systematic review.
Identifiants
pubmed: 36223980
pii: ebmental-2022-300530
doi: 10.1136/ebmental-2022-300530
pmc: PMC9811092
doi:
Types de publication
Journal Article
Meta-Analysis
Randomized Controlled Trial
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e49-e57Informations de copyright
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: We have read the journal’s policy and the authors of this manuscript have the following competing interests. DE and CCG were committee members for the NICE Depression Guideline (update) Development Group between 2015 and 2022, and SiG was a member between 2015 and 2018. SiG, PC and DM are supported by the NIHR Yorkshire and Humberside Applied Research Collaboration (ARC) and DE is supported by the North East and North Cumbria ARCs. CCG is part funded by West Midland ARC.
Références
Lancet Public Health. 2020 Jan;5(1):e12-e13
pubmed: 31910976
J Psychiatr Res. 2018 Apr;99:69-75
pubmed: 29407289
Behav Ther. 2020 Jan;51(1):54-68
pubmed: 32005340
Lancet Psychiatry. 2021 Jan;8(1):48-57
pubmed: 33181096
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
J Clin Epidemiol. 2017 Nov;91:23-30
pubmed: 28912002
PLoS One. 2014 Jun 17;9(6):e100100
pubmed: 24936656
Psychother Psychosom. 2021;90(5):351-358
pubmed: 34182552
J Ment Health. 2019 Aug;28(4):410-418
pubmed: 29722574
Eur J Prev Cardiol. 2018 Sep;25(13):1387-1396
pubmed: 30068233
Int J Psychol. 2018 Oct;53(5):373-378
pubmed: 27704544
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
PLoS One. 2022 Mar 24;17(3):e0263856
pubmed: 35324908
Am J Geriatr Psychiatry. 2020 Jul;28(7):698-708
pubmed: 32238297
Soc Psychiatry Psychiatr Epidemiol. 2017 Jun;52(6):627-638
pubmed: 28528389
Int J Nurs Sci. 2016 Sep;3(3):242-251
pubmed: 29082303
Lancet Healthy Longev. 2021 Feb;2(2):e54-e55
pubmed: 36098152
Lancet Public Health. 2020 Jan;5(1):e62-e70
pubmed: 31910981
Lancet Psychiatry. 2021 Aug;8(8):647-650
pubmed: 34087112
Brain Behav Immun. 2012 Oct;26(7):1095-101
pubmed: 22820409
BMJ. 2016 Oct 24;355:i5239
pubmed: 27777223
Int J Geriatr Psychiatry. 2011 Dec;26(12):1211-20
pubmed: 21308789
Br J Psychiatry. 2017 Nov;211(5):274-279
pubmed: 28982660
Lancet Psychiatry. 2020 Jun;7(6):547-560
pubmed: 32304649
BMJ. 2020 Jul 30;370:m2925
pubmed: 32732314
BMJ. 2019 Aug 28;366:l4898
pubmed: 31462531
PLoS Med. 2021 Oct 12;18(10):e1003779
pubmed: 34637450
JAMA. 2017 Feb 21;317(7):728-737
pubmed: 28241357
Am J Geriatr Psychiatry. 2021 Aug;29(8):771-776
pubmed: 34130906
Am J Geriatr Psychiatry. 2022 Feb;30(2):197-207
pubmed: 34266750
Int J Environ Res Public Health. 2019 Apr 11;16(7):
pubmed: 30979042
Mil Med. 2004 Oct;169(10):814-20
pubmed: 15532347
JAMA Netw Open. 2022 Apr 1;5(4):e227629
pubmed: 35452109
Internet Interv. 2020 Jan 17;19:100301
pubmed: 32071885
Lancet Psychiatry. 2020 Jul;7(7):567-568
pubmed: 32502467
Lancet Public Health. 2021 Jun;6(6):e365-e373
pubmed: 33894138
Am J Geriatr Psychiatry. 2022 Dec;30(12):1313-1323
pubmed: 35680539
Clin Psychol Rev. 2021 Aug;88:102066
pubmed: 34339939